Godin Anny, Liberman Moishe
Division of Thoracic Surgery, CETOC-CHUM Endoscopic Tracheo-Bronchial and Oesophageal Center, University of Montreal, Montreal, Quebec, Canada.
Ann Transl Med. 2021 May;9(10):905. doi: 10.21037/atm.2020.03.107.
Thoracic surgeons currently have multiple options and strategies to guide treatment in esophageal palliative and emergency conditions. To guide the selection of an individualized palliative approach, physicians, including thoracic surgeons, must take into consideration many factors including prognosis, performance status and comorbidities of patients. For dysphagia more specifically, esophageal stent placement is the most widely used intervention for rapidly relieving dysphagia in inoperable esophageal cancer patients. The combination of esophageal stent placement with other therapies has an impact on palliative care. Innovations including radioactive stents, drug-eluding stents and biodegradable stents will require further evaluation and validation studies. Currently, patients with inoperable esophageal cancer have access to oncological and biological therapies that are improving their prognosis. A shift toward restaging and potential curative intent is occurring in current clinical practice. In acute intrathoracic esophageal perforation cases, high index of suspicion, multidisciplinary team expertise, antibiotics and hybrid treatment strategies, have significantly improved outcomes of patients in recent years. Hybrid treatment strategies denote the combination of minimally invasive interventions for source control and endoluminal procedures to seal the esophageal perforation. Endoluminal procedures as treatment of acute intrathoracic esophageal perforation include stent placement, over-the-scope clip and endoluminal vacuum therapy. Future perspective in the management of esophageal perforation seems to be the combination of endoluminal therapies tailored to the specific clinical scenario. Thoracic surgeons benefit from mastering endoluminal therapies and advanced endoscopic techniques. An understanding of these rapidly evolving therapies, i.e., outcomes, limitations and innovations, is required to optimally manage esophageal palliative and emergency conditions.
目前,胸外科医生在食管姑息性和紧急情况下的治疗指导方面有多种选择和策略。为了指导选择个体化的姑息治疗方法,包括胸外科医生在内的医生必须考虑许多因素,包括患者的预后、身体状况和合并症。更具体地说,对于吞咽困难,食管支架置入是用于快速缓解无法手术的食管癌患者吞咽困难的最广泛使用的干预措施。食管支架置入与其他疗法的联合对姑息治疗有影响。包括放射性支架、药物洗脱支架和可生物降解支架在内的创新技术需要进一步的评估和验证研究。目前,无法手术的食管癌患者可以获得改善其预后的肿瘤学和生物疗法。当前的临床实践正在朝着重新分期和潜在的治愈意图转变。在急性胸段食管穿孔病例中,近年来,高度的怀疑指数、多学科团队的专业知识、抗生素和综合治疗策略显著改善了患者的治疗效果。综合治疗策略是指将用于源头控制的微创干预措施与腔内手术相结合以封闭食管穿孔。腔内手术作为急性胸段食管穿孔的治疗方法包括支架置入、内镜下套扎和腔内负压治疗。食管穿孔管理的未来前景似乎是根据具体临床情况量身定制的腔内治疗方法的联合应用。胸外科医生受益于掌握腔内治疗和先进的内镜技术。为了优化食管姑息性和紧急情况的管理,需要了解这些快速发展的治疗方法,即治疗效果、局限性和创新。